Editorial Commentary
Lessons from FOWARC: moving towards the more precise use of radiation therapy in the era of total neoadjuvant therapy
AME Clinical Trials Review
2025;
3:
20
(25 April 2025)
Editorial Commentary
Stereotactic ablative radiotherapy as a novel strategy in patients with oligometastatic hepatocellular carcinoma
AME Clinical Trials Review
2025;
3:
19
(25 April 2025)
Editorial Commentary
Finding the RIGHT Choice in patients with clinically aggressive ER-positive HER2-negative metastatic breast cancer
AME Clinical Trials Review
2025;
3:
18
(25 April 2025)
Editorial Commentary
Empowering treatment: insights from 35 months follow-up highlight the benefits of cemiplimab monotherapy and continued immunotherapy plus chemotherapy beyond progression in advanced non-small cell lung cancer patients with high PD-L1 expression
AME Clinical Trials Review
2025;
3:
17
(25 April 2025)
Editorial Commentary
Patritumab deruxtecan: advancing the treatment landscape for EGFR-resistant non-small cell lung cancer
AME Clinical Trials Review
2025;
3:
16
(25 April 2025)
Editorial Commentary
Emerging role of circulating tumor DNA as a predictive biomarker in consolidation immunotherapy for unresectable stage III NSCLC
AME Clinical Trials Review
2025;
3:
15
(25 April 2025)
Editorial Commentary
Revumenib: a new potential targeted therapy for KMT2A-rearranged acute leukemia
AME Clinical Trials Review
2025;
3:
14
(25 April 2025)
Editorial Commentary
Intravascular imaging guided optimization in complex percutaneous coronary intervention (PCI)—does clinical presentation matter?
AME Clinical Trials Review
2025;
3:
13
(25 April 2025)
Editorial Commentary
Is zilebesiran a novel effective and uniquely administered agent for an expanding therapeutic armamentarium for blood pressure control?
AME Clinical Trials Review
2025;
3:
12
(25 April 2025)
Editorial Commentary
A SMART-er approach to upfront unresectable pancreatic adenocarcinoma
AME Clinical Trials Review
2025;
3:
11
(25 April 2025)
Editorial Commentary
Unpacking prostate-specific antigen dynamics and patient outcomes: insights from the ARASENS trial
AME Clinical Trials Review
2025;
3:
10
(25 February 2025)
Editorial Commentary
How do we improve chemoimmunotherapy in gastroesophageal adenocarcinoma?
AME Clinical Trials Review
2025;
3:
9
(25 February 2025)
Editorial Commentary
Final survival analysis from the LACC trial defines the current standard of care in surgical treatment of cervical cancer, however does not mark the final say
AME Clinical Trials Review
2025;
3:
8
(25 February 2025)
Editorial Commentary
Targeting menin in relapsed or refractory acute myeloid leukaemia—where the rubber hits the road
AME Clinical Trials Review
2025;
3:
7
(25 February 2025)
Editorial Commentary
Re-evaluating antiplatelet therapy post-coronary artery bypass grafting: insights from the DACAB trial’s five-year follow-up
AME Clinical Trials Review
2025;
3:
6
(25 February 2025)
Editorial Commentary
Innovative dual approach: CD40 agonist and mFOLFIRINOX combination therapy in metastatic pancreatic cancer
AME Clinical Trials Review
2025;
3:
5
(25 February 2025)
Editorial Commentary
DACAB trial supports long-term use of ticagrelor and aspirin dual therapy after coronary artery bypass grafting
AME Clinical Trials Review
2025;
3:
4
(25 February 2025)
Editorial Commentary
Is EndoRotor the answer to residual colonic lesions?
AME Clinical Trials Review
2025;
3:
3
(25 February 2025)
Editorial Commentary
Should we target demethylation in acute myeloid leukemia?
AME Clinical Trials Review
2025;
3:
2
(25 February 2025)
Editorial Commentary
Upfront axillary surgical management—a commentary on previously underrepresented patient groups and how the SENOMAC trial righted this wrong
AME Clinical Trials Review
2025;
3:
1
(25 February 2025)
Review Article
Cleaning the scope: have randomized clinical trials clarified the benefits of minimally invasive thoracic surgery for non-small cell lung cancer?—a narrative review
AME Clinical Trials Review
2024;
2:
112
(25 December 2024)
Editorial Commentary
Less radiation, same bang, fewer bucks?
AME Clinical Trials Review
2024;
2:
111
(25 December 2024)
Editorial Commentary
Neoadjuvant FOLFIRINOX in resectable pancreatic cancer: impact of the NORPACT-1 trial
AME Clinical Trials Review
2024;
2:
110
(25 December 2024)
Editorial Commentary
Need of the hour—advancements in treatment of pancreatic cancer
AME Clinical Trials Review
2024;
2:
109
(25 December 2024)
Editorial Commentary
Combining [177Lu]Lu-PSMA-617 and enzalutamide in metastatic castration-resistant prostate cancer: promising but with caveats for now
AME Clinical Trials Review
2024;
2:
108
(25 December 2024)
Editorial Commentary
Tislelizumab in hepatocellular carcinoma: a duet or a solo performance?
AME Clinical Trials Review
2024;
2:
107
(25 December 2024)
Editorial Commentary
To fast or not to fast—that is the question?
AME Clinical Trials Review
2024;
2:
106
(25 December 2024)
Editorial Commentary
The COMBAT trial: use of bipolar androgen therapy to enhance immune checkpoint blockade in the management of metastatic castration-resistant prostate cancer
AME Clinical Trials Review
2024;
2:
105
(25 December 2024)
Editorial Commentary
Novel agents in acute lymphoblastic leukemia: an expanding role for inotuzumab ozogamicin in patients with measurable residual disease
AME Clinical Trials Review
2024;
2:
104
(25 December 2024)
Editorial Commentary
Optimizing antiplatelet therapy after coronary artery bypass graft: selection, dosing, and duration
AME Clinical Trials Review
2024;
2:
103
(25 December 2024)